Drug Profile
ASG 15ME
Alternative Names: ASG 15E; ASG-15MELatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Agensys; Ligand Pharmaceuticals; Seattle Genetics
- Developer Agensys; Astellas Pharma; Seagen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Urogenital cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Nov 2021 No recent reports of development identified for phase-I development in Urogenital-cancer(Metastatic disease, Second-line therapy or greater) in Canada (IV, Infusion)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Urogenital-cancer(Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)